Get the Stockscreener App
0.7147
0.29%
0.0021
After Hours:
.72
0.0053
+0.74%
Inmed Pharmaceuticals Inc stock is traded at $0.7147, with a volume of 38,344.
It is up +0.29% in the last 24 hours and down -7.30% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
See More
Previous Close:
$0.7126
Open:
$0.71
24h Volume:
38,344
Relative Volume:
0.36
Market Cap:
$2.37M
Revenue:
$4.51M
Net Income/Loss:
$-7.66M
P/E Ratio:
-0.1892
EPS:
-3.778
Net Cash Flow:
$-7.51M
1W Performance:
+5.04%
1M Performance:
-7.30%
6M Performance:
-67.51%
1Y Performance:
-72.93%
1-Day Range:
$0.6864
$0.7147
1-Week Range:
$0.5805
$0.72
52-Week Range:
$0.575
$7.98
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
0.7147 | 2.37M | 4.51M | -7.66M | -7.51M | -3.778 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
Fund Flows: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Income Plays: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Market Trends & Verified Momentum Stock Alerts - baoquankhu1.vn
Price performance - Yahoo Finance Singapore
Published on: 2026-04-05 13:17:10 - baoquankhu1.vn
InMed Pharmaceuticals Inc. Files Form 8-K Current Report with SEC – Company Information, Nasdaq Listing, and Legal Opinion Included - Minichart
InMed Pharmaceuticals files prospectus supplement for at-the-market share offering - Investing.com
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing - TipRanks
InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement - TradingView — Track All Markets
InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf - Stock Titan
InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee - Stock Titan
[EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
[8-K] InMed Pharmaceuticals Inc. Reports Material Event - Stock Titan
InMed receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com Australia
InMed warned by Nasdaq over minimum bid price non-compliance - TipRanks
InMed Pharmaceuticals Notified of Nasdaq Non-Compliance with $1 Minimum Bid Price Rule - geneonline.com
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Investing News Network
InMed receives Nasdaq minimum bid price deficiency notice - Investing.com
InMed Pharma gets Nasdaq non-compliance notice - MSN
InMed Pharmaceuticals Inc.Common Shares (NQ: INM - The Chronicle-Journal
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12 - Minichart
InMed reports preclinical data on Alzheimer’s drug candidate By Investing.com - Investing.com Australia
InMed Pharmaceuticals Inc. (INM) Stock: Shows Promising Anti-Inflammatory Effects in 3D Brain Organoid Study - parameter.io
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with N - GuruFocus
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Investing News Network
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate - TipRanks
InMed reports preclinical data on Alzheimer’s drug candidate - Investing.com
InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC). - Bitget
InMed (NASDAQ: INM) reports INM-901 organoid data, targets Phase 1 in 2027 - Stock Titan
Aug Decliners: Can InMed Pharmaceuticals Inc outperform under higher oil pricesWeekly Market Outlook & Low Drawdown Trading Strategies - baoquankhu1.vn
[S-3] InMed Pharmaceuticals Inc. Shelf Registration Statement - Stock Titan
Aug Weekly: Can InMed Pharmaceuticals Inc be the next market leaderBear Alert & Accurate Entry/Exit Alerts - baoquankhu1.vn
Ideas Watch: Can InMed Pharmaceuticals Inc be the next market leader2026 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Published on: 2026-03-17 19:00:00 - baoquankhu1.vn
CEO Moves: Will InMed Pharmaceuticals Inc stock go up in YEAR2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
InMed Pharmaceuticals Advances INM-901 for Alzheimer’s and INM-089 for Macular Degeneration with FDA Engagement Planned for 2026-2027 1 - Minichart
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
InMed Pharmaceuticals (INM) Sets 2026 Development Goals - gurufocus.com
InMed Provides Update on Pharmaceutical Development ProgramsAdvancing Lead Drug Candidates Towards IND and Clinical Trial - Investing News Network
InMed outlines 2026 development plans for lead programs - TipRanks
InMed Provides 2026 Development Outlook; Targets FDA pre-IND for INM-901 and Phase 1 in 2027 - TradingView
InMed (INM) sets 2026 goals for Alzheimer’s and eye-disease drug programs - Stock Titan
InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan
Can InMed Pharmaceuticals Inc reach all time highs this yearJuly 2025 Technicals & Weekly Momentum Picks - baoquankhu1.vn
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Investing News Network
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica divisio - Bitget
InMed Pharmaceuticals Exits BayMedica to Refocus on Pipeline - TipRanks
InMed Pharmaceuticals IncOn March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial OperationsSEC Filing - TradingView
InMed (NASDAQ: INM) winds down BayMedica unit and pivots fully to drug development - Stock Titan
INM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):